Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology (Internal Medicine) Physician in Duluth, MN
NPI: 1467482349Primary Practice Location
ESSENTIA HEALTH DULUTH
502 E 2nd St, Duluth, MN
Primary Employer
Essentia Health Duluth Clinic
essentiahealth.org
HQ Phone
Get Daniel's Phone Numberphone_androidMobile
Get Daniel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 129 | 263 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 39 | 121 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 36 | 36 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 22 | 24 |
| 5 | 99442Physician telephone patient service, 11-20 minutes of medical discussion | 22 | 41 |
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Authors: Craig Reeder, Michael Conte, Charles Erlichman, Tait Shanafelt, Wei Ding, Jose Leis, Curtis Hanson, Thomas Habermann, Jeremy Larsen
Publication Date: 2017-06
Authors: Tom Fitch, Timothy Hobday, Donald Northfelt, Edith Perez, Robert Behrens, Kendrith Rowland, Kostandinos Sideras
Journal: Clin Breast Cancer
Publication Date: 2012-10-17
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Eflornithine plus sulindac, DRUG: Eflornithine placebo & sulindac placebo, DRUG: eflornithine & sulindac placebo, DRUG: Eflornithine placebo & sulindac
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Decitabine, DRUG: Cytarabine, OTHER: Observation, DRUG: Clofarabine, PROCEDURE: Allogeneic hematopoietic stem cell transplantation, DRUG: Daunorubicin
